{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:58:25Z","timestamp":1767117505395},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clinthera.2017.11.014","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T01:47:05Z","timestamp":1513820825000},"page":"114-122","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol"],"prefix":"10.1016","volume":"40","author":[{"given":"Jos\u00e9 Miguel","family":"Rivera-Caravaca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Esteve-Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.11.014_bib1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","article-title":"Causes of deaths and influencing factors in patients with atrial fibrillation","volume":"129","author":"Fauchier","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2017.11.014_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jth.12041","article-title":"The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation","volume":"11","author":"Van Den Ham","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.014_bib3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.014_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.clinthera.2017.11.014_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1160\/TH14-12-1087","article-title":"The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists","volume":"113","author":"Rold\u00e1n","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.014_bib6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.014_bib7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2017.11.014_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.014_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2017.11.014_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.2016.9356","article-title":"Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy","volume":"316","author":"Pokorney","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.11.014_bib11","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1160\/TH14-10-0859","article-title":"Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula","volume":"113","author":"Sjogren","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2017.11.014_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2017.11.014_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2017.11.014_bib14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.11.014_bib15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14779072.2014.943189","article-title":"Updated NICE guideline: management of atrial fibrillation (2014)","volume":"12","author":"Senoo","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2017.11.014_bib16","doi-asserted-by":"crossref","first-page":"e0164076","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2017.11.014_bib17","doi-asserted-by":"crossref","first-page":"e5467","DOI":"10.1097\/MD.0000000000005467","article-title":"The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2017.11.014_bib18","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2017.11.014_bib19","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.amjmed.2015.05.036","article-title":"The SAMe-TT2R2 score predicts poor anticoagulation in atrial fibrillation patients initiating Vitamin K antagonists: A prospective \"real world\" inception cohort study","volume":"128","author":"Rold\u00e1n","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2017.11.014_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clinthera.2017.11.014_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/eux314","article-title":"Quality of oral anticoagulation with vitamin K antagonists in \u201creal-world\u201d patients with atrial fibrillation: A report from the prospective multicenter FANTASIIA registry","author":"Esteve-Pastor","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2017.11.014_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817311050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817311050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T21:03:33Z","timestamp":1530219813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817311050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0149291817311050"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}